Patient-Derived Synovium-on-a-Chip Recapitulates Disease and Treatment Response and Permits Study of Resistance in Rheumatoid Arthritis

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Rheumatoid arthritis (RA) is a chronic inflammatory disease with substantial interpatient heterogeneity in synovial pathology and therapeutic response. Reliable methods to predict drug efficacy for a given patients remain a critical unmet need. We developed a vascularized, immunocompetent synovium-on-a-chip platform that integrates patient-derived fibroblast-like synoviocytes (FLS) with matched peripheral blood leukocytes to provide a physiological human model of RA. The platform reconstructed the lining–sublining synovial architecture, recapitulated key features of RA inflammation, and exhibited transcriptional profiles resembling those of patient synovial tissue. Across patients spanning low, mixed, and high inflammatory endotypes, stromal– vascular organization was associated with distinct immune cell positioning and activation patterns, and on-chip immune phenotypes correlated with histological joint inflammation scores. We then tested infliximab, tocilizumab, and tofacitinib in parallel and integrated cytokine secretion, extracellular matrix remodeling, immune cell survival and immune cell recruitment into a composite treatment response score. On-chip scores for clinically matched treatments correlated with clinical improvement measured by ΔDAS28–ESR (Pearson r = 0.844). To investigate the cellular basis of heterogeneous drug responses, single-cell RNA sequencing identified SFRP1⁺ remodeling FLS that persisted under treatment and exhibited high inflammatory programs in poorly responding chips. Cell–cell communication analysis linked reduced FN1–CD44 signaling toward SFRP1⁺ remodeling FLS to higher NF-κB activity and drug resistance. We tested the functional relevance of this finding in chips derived from an independent TNFi-nonresponsive patient, where fibronectin supplementation reduced IL-6 secretion and restored the composite treatment response. Together, these findings support patient-derived synovium-on-a-chip as a platform for individualized drug evaluation and identify ECM-mediated niche signaling as a potential therapeutic target for overcoming drug resistance in RA.

One Sentence Summary

A patient-derived immunocompetent synovium-on-a-chip recapitulates rheumatoid arthritis joint biology in vitro, accurately tests patient therapeutic response and reveals a SFRP1⁺ FLS-mediated resistance mechanism in rheumatoid arthritis.

Article activity feed

  1. Authors used RRID NOT VALID - THI from @thermofishersci.bsky.social in their study. Including #RRIDs will make this less ambiguous. SciScore made a table with this resource, see “Automated Services” module (download as csv, xml or #jats) #reproducibility #STMpublishing

  2. Patient-Derived Synovium-on-a-Chip Recapitulates Disease and Treatment Response and Permits Study of Resistance #SingleCell 🧪🧬🖥️ https://www.biorxiv.org/content/10.64898/2026.10.30.763140v1

  3. Patient-Derived Synovium-on-a-Chip Recapitulates Disease and Treatment Response and Permits Study of Resistance https://www.biorxiv.org/content/10.64898/2026.10.30.763140v1

  4. Patient-Derived Synovium-on-a-Chip Recapitulates Disease and Treatment Response and Permits Study of Resistance https://www.biorxiv.org/content/10.64898/2026.10.30.763140v1